Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Conferences | Events

Lonza’s 4D-Nucleofector LV Unit Delivers Closed, Optimized, Larger-Scale Transfection

publication date: Jul 19, 2016
author/source: Lonza

Today Lonza introduced the 4D-NucleofectorTM LV Unit to its transfection platforms.

lonzaThe new unit expands the proven 4D-Nucleofector™ System to closed, larger-scale transfection of up to 1x109 cells. Transfection protocols can be established in smaller scale using the 4D-Nucleofector™ X Unit and smoothly transferred to larger scale without the need for re-optimization. With this new addition, small- and large-scale transfection applications are now united in one system based on the highly efficient and established Nucleofector™ Technology.

Transfection is a powerful tool that is used to study and control gene expression by delivering DNA, RNA and even proteins into cells. Various applications within translational research require the generation of large numbers of transiently modified cell lines or primary cells. Such applications include modification of cells via genome editing or the generation of CAR-T cells for ex-vivo cell therapies, production of transient proteins or antibodies for construct screening, and generation of disease models via genome editing for cell-based assays.

Herbert Mueller-Hartmann, Head of Research and Technology at Lonza, explained, “The new addition of a larger-scale transfection format allows us to accompany scientists as they translate the results of their research applications into potential therapeutic applications. What is really unique to our technology is the fact that the same transfection conditions can be used throughout our various conductive polymer-based platforms, which allows for real scalability.” Mueller-Hartmann went on to say, “The fully closed system is also suited for use in a regulatory environment as it can be controlled by 21 CFR Part 11-compatible software.”

Lonza’s Nucleofector™ Technology is an improved electroporation technique that has transformed transfection and allowed scientists to achieve results never before possible. Unlike classical electroporation, Nucleofection delivers high efficiencies that can be achieved using much lower amounts of substrate with only a moderate impact on viability. When it was introduced in 2001, Nucleofector™ Technology was the first efficient, non-viral transfection method for primary cells and hard-to-transfect cell lines. Due to its flexibility with different substrates, such as plasmid DNA and mRNA, Nucleofector™ Technology is being used by many renowned scientists and is helping to drive research in numerous cell types and applications, including non-viral iPSC generation via episomal vectors, as well as genome editing using various ZFN-, TALEN- or CRISPR-related cargo combinations.

more about lonza



Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners